LUND, SWEDEN -- (MARKET WIRE) -- February 14, 2007 -- After the expiration of the subscription period for Active Biotech's new share issue totaling SEK 240 M, a count has shown that the issue is oversubscribed by 53%. 99.1% of the shares offered were subscribed for with the support of subscription rights. The shares subscribed for without the support of subscription rights will be distributed in proportion to the number of shareholders who subscribed for shares in excess of their preferential-rights allocation.
